ERIS LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of ERIS LIFESCIENCES have increased by 19.23% YoY .
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has increased by 2.56 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ERIS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 540596|NSE : ERIS]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹2,009 Cr | ₹1,685 Cr | ₹1,347 Cr | ₹1,212 Cr | ₹1,074 Cr |
| Expenses | ₹1,334 Cr | ₹1,148 Cr | ₹862 Cr | ₹781 Cr | ₹706 Cr |
| Operating Profit (Excl OI) | ₹675 Cr | ₹537 Cr | ₹485 Cr | ₹431 Cr | ₹368 Cr |
| Other Income | ₹24 Cr | ₹11 Cr | ₹26 Cr | ₹8.71 Cr | ₹16 Cr |
| Interest | ₹85 Cr | ₹26 Cr | ₹4.22 Cr | ₹1.98 Cr | ₹2.30 Cr |
| Depreciation | ₹183 Cr | ₹117 Cr | ₹65 Cr | ₹43 Cr | ₹50 Cr |
| Profit Before Tax | ₹431 Cr | ₹405 Cr | ₹442 Cr | ₹394 Cr | ₹331 Cr |
| Profit After Tax | ₹397 Cr | ₹374 Cr | ₹406 Cr | ₹355 Cr | ₹297 Cr |
| Consolidated Net Profit | ₹392 Cr | ₹382 Cr | ₹406 Cr | ₹355 Cr | ₹296 Cr |
| Earnings Per Share (Rs) | ₹28.82 | ₹28.10 | ₹29.88 | ₹26.16 | ₹21.84 |
| PAT Margin (%) | 18.78 | 21.20 | 29.09 | 28.53 | 27.61 |
| ROE(%) | 16.63 | 18.25 | 23.33 | 24.78 | 24.28 |
| ROCE(%) | 12.36 | 17.30 | 25.29 | 27.60 | 25.44 |
| Total Debt/Equity(x) | 1.06 | 0.38 | 0.02 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 19,962.5 Cr |
| Revenue (TTM) | : | ₹ 2,498.1 Cr |
| Net Profit(TTM) | : | ₹ 366.9 Cr |
| EPS (TTM) | : | ₹ 27.0 |
| P/E (TTM) | : | 54.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ERIS LIFESCIENCES | 8.2% | 15.1% | 57.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.9% | -4.8% | 50.2% |
| CIPLA | 1.5% | 0.1% | 19.9% |
| DR REDDYS LABORATORIES | -0.4% | -8.2% | 7.1% |
| ZYDUS LIFESCIENCES | 0.6% | -5.3% | 51% |
| DIVIS LABORATORIES | 3% | 5.9% | 65% |
| MANKIND PHARMA | 0.6% | 3.1% | 34.4% |
| TORRENT PHARMACEUTICALS | 4.3% | -2.7% | 54.2% |
| LUPIN | -0.1% | -4.4% | 72.4% |
ERIS LIFESCIENCES Revenues
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 19.23 % |
| 5 Yr CAGR | 16.95 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,009 Cr | 19.23 | |
| Mar2023 | ₹1,685 Cr | 25.10 | |
| Mar2022 | ₹1,347 Cr | 11.15 | |
| Mar2021 | ₹1,212 Cr | 12.83 | |
| Mar2020 | ₹1,074 Cr | - | |
ERIS LIFESCIENCES Operating Profit
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 25.73 % |
| 5 Yr CAGR | 16.38 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹675 Cr | 25.73 | |
| Mar2023 | ₹537 Cr | 10.66 | |
| Mar2022 | ₹485 Cr | 12.60 | |
| Mar2021 | ₹431 Cr | 17.09 | |
| Mar2020 | ₹368 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 5.46 % |
| 5 Yr CAGR | -0.49 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 33.59% | 5.46 | |
| Mar2023 | 31.85% | -11.55 | |
| Mar2022 | 36.01% | 1.32 | |
| Mar2021 | 35.54% | 3.77 | |
| Mar2020 | 34.25% | - | |
ERIS LIFESCIENCES Profit After Tax
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 2.57 % |
| 5 Yr CAGR | 7.23 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹392 Cr | 2.57 | |
| Mar2023 | ₹382 Cr | -5.90 | |
| Mar2022 | ₹406 Cr | 14.35 | |
| Mar2021 | ₹355 Cr | 19.78 | |
| Mar2020 | ₹296 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -11.42 % |
| 5 Yr CAGR | -9.19 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 18.78 % | -11.42 | |
| Mar2023 | 21.2 % | -27.12 | |
| Mar2022 | 29.09 % | 1.96 | |
| Mar2021 | 28.53 % | 3.33 | |
| Mar2020 | 27.61 % | - | |
ERIS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 2.56 % |
| 5 Yr CAGR | 7.18 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹29 | 2.56 | |
| Mar2023 | ₹28 | -5.96 | |
| Mar2022 | ₹30 | 14.22 | |
| Mar2021 | ₹26 | 19.78 | |
| Mar2020 | ₹22 | - | |
ERIS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -28.55 % |
| 5 Yr CAGR | -16.51 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 12.36% | -28.55 | |
| Mar2023 | 17.3% | -31.59 | |
| Mar2022 | 25.29% | -8.37 | |
| Mar2021 | 27.6% | 8.49 | |
| Mar2020 | 25.44% | - | |
ERIS LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹1,466.8 |
| Current MarketCap | : | ₹ 19,962.5 Cr |
| Updated EOD on | : | Nov 27,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ERIS LIFESCIENCES | 8.2% |
15.1% |
57.8% |
| SENSEX | 3.4% |
0.2% |
21.7% |
ERIS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 3.9% | 1.7% | 37% |
| S&P BSE 250 SMALLCAP | 3.9% | 0.2% | 33.3% |
| S&P BSE MIDSMALLCAP | 3.5% | 0.7% | 37.3% |
| S&P BSE 400 MIDSMALLCAP | 3.4% | -0.2% | 35% |
| S&P BSE 500 | 3.1% | -0.5% | 28.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP250 | 4.2% | 1.2% | 35% |
| NIFTY MID SMALL400 | 3.3% | 0.1% | 34.1% |
| NIFTY500 MULTICAP 50:25:25 | 3.3% | -0.2% | 30.6% |
| NIFTY 500 | 3.1% | -0.4% | 28.7% |
You may also like the below Video Courses
FAQ about ERIS LIFESCIENCES Financials
How the annual revenues of ERIS LIFESCIENCES have changed ?
The Revenues of ERIS LIFESCIENCES have increased by 19.23% YoY .
How the Earnings per Share (EPS) of ERIS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has increased by 2.56 % YoY .
Check out Intrinsic Value of Peers of ERIS LIFESCIENCES
Compare Stock Analytics of Peers of ERIS LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
